Phase 1 Study of dmLT ID Vaccination in Healthy Adults

NCT02531685 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

100

Enrollment

NIH

Sponsor class

Conditions

Gastroenteritis Escherichia Coli

Interventions

OTHER: Placebo
BIOLOGICAL: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)